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Synthesis and Characterization of Nanoparticle-Coupled Proteins in Human Serum
Albumin
An Honors Thesis submitted in partial fulfillment of the requirements for Honors in Physics.
By: Kyle Mahoney
Under the mentorship of Dr. Li Ma
Abstract
Recently, cancer has become an ever-growing issue and has led to many researchers
attempt to unravel the mystery of the disease. This research has led to a promising field of
treatment: nanotechnology-coupled pharmaceuticals. Nanoparticles act as a whole unit when
in conjugation with other molecules and add to the carrier molecule, most often proteins,
benefits the nanoparticles themselves possess. One such carrier protein that can be
conjugated with nanoparticles is Human Serum Albumin (HSA). Albumin is of interest in
cancer research for two reasons: it is native to the human vasculature so it does not elicit
immunological reactions, and it has tumor specificity. HSA made its main debut in cancer
treatment when it was used to encapsulate Paclitaxel, an FDA approved cancer drug, to
improve the drug delivery capabilities to hypoxic tumor cores via poly-nitroxylated
nanoparticles. The primary goal of this study was to modify nitroxyl-decorated human serum
albumin to stabilize Paclitaxel in order to synthesize a spin-albumin-stabilized Paclitaxel
nanoparticle that will act as a cancer carrying protein with improved targeting of hypoxic
tumor cores for cancer drug delivery while also having the nanoparticles add additional
therapeutic properties to the drug complex: namely acting as an antioxidant and vasodilator.
Data obtained from High Pressure Liquid Homogenization indicated that Paclitaxel was
successfully loaded into nitroxyl-decorated HSA and nanoparticles formed in the correct size
range of 100-200nm. Electron Spin Resonance data and spectroscopy data also confirmed the
loading of Paclitaxel and allowed for the quantification of the number of loaded drug
molecules.

Thesis Mentor:___________________
Dr. Li Ma
Honors Director:___________________
Dr. Steven Engel
December 2015
Physics
University Honors Program

Acknowledgements
I would like to thank my parents, Stephen and Angela Mahoney, for supporting me
through my tenure at Georgia Southern University. Without them I would never have been
able to pursue my research and would not have the deeper appreciation for education based
research that I have today. I would also like to thank my fiancé, Rhiannon Pinsonneault, for
the ample emotional support she provided me while I worked on this project. I could always
count on her to help brighten my day when I was bogged down in a research related issue.
Another big thanks goes out to a few of my fellow physics majors, Gil Salazar and Brennan
Coheleach, as well as my good friend Frank Parr for helpful insights and hands-on help with
the project along the way. I would also like to say thank you to the University of South
Dakota for allowing us to use their High Pressure Liquid Homogenizer to make our samples.
Finally, and most importantly, I would like to express my most sincere gratitude and
appreciation to Dr. Li Ma. Dr. Ma mentored and encouraged me on this project from the time
when I read my first piece of literature (which she provided me with) to analyzing the last bit
of data. It was truly an honor to work with someone so intelligent and inspiring; all that I
have learned through this research project can be tied back to Dr. Ma in some way.
Introduction
In recent years, caner has become an ever-growing issue in the eyes of the public and
with such attention, has led to the focus of many medical and scientific researchers being
shifted towards unravelling the mystery of the disease. Although there are many different
types of cancer, all of them have certain characteristics at the cellular level which are
indicative of cancerous cells. Such characteristics include having self-sufficient growth
signals, an insensitivity to antigrowth signals, ability to invade tissues (and reach metastasis
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in the invaded tissues), a limitless potential for replication, sustained angiogenesis, and an
ability to evade apoptosis (Lodish et. al., 2000). Although cancers can become specific to a
certain tissue or region, it is these similarities among the different types of cancer that have
allowed researchers to made strides towards more effective treatments for cancer patients.
One such method of treatment that has gained much attention in the recent years of
study is the use of nanotechnology-coupled pharmaceuticals. Nanoparticles, although
nanoscopic in size, act as a whole unit when in conjugation with other molecules and add to
the carrier molecule any benefits the nanoparticles themselves possess as part of their
physical or chemical properties. Nanoparticles also have the ability to accumulate at sites of
inflammation making them suitable for targeted drug delivery (Das et al., 2005). In the case
of cancer treatment, the use of stable nitroxyl radicals (nitroxides) can be made into
nanoparticles that provide the carrier protein with the added benefit of acting as an
antioxidant. Theses antioxidant allow for the stabilization of harmful free radicals in the
blood in addition to the vasodilation of the vasculature in which they are present. This
expansion of the blood vessels has been demonstrated by Kaul et al. in the treatment of sickle
cell adhesion using antioxidants. Similar usage of nitroxides with albumin has also led to
observed decreases in the infarct size of hemorrhages in rats (Beaulieu et al., 1998).
The results of each of these studies not only depended on nitroxide nanoparticles, but
also on the type of carrier protein the nitroxide groups were conjugated with. One such
carrier protein is Human Serum Albumin (HSA). HSA is a monomeric protein found in
human blood that transports hormones, fatty acids, and other compounds (Purcell et al.,
2000). Its role as a natural transport protein makes it an ideal candidate for conjugation with
nanoparticles. Since HSA is a component of the blood plasma, about 5%, it is naturally
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soluble and therefore can act as a carrier for hydrophobic drugs and medicines. Recently,
HSA has been combined with nitroxyl free radical groups to create spin-labeled albumin that
will hopefully become the next step in effective cancer treatment (Miele et al., 2009).
In 1982, a cancer drug, Paclitaxel (Taxol), was approved by the Food and Drug
Administration for the treatment of cancer. However, due to Taxol being relatively insoluble
in the blood stream, new methods were employed to help the delivery of the drug. Such
research resulted in the formation of a new cancer drug: Abraxane (Abraxane BioScience,
2006). Abraxane is an albumin-stabilized Paclitaxel nanoparticle that acts as a mitotic
inhibitor. In 2005, this drug was also approved by the FDA for the treatment of cancer;
however, there was still a need for improvement in the delivery of the cancer drug to the
cancer cells as shown by Matsumura and Kataoka in their study of anticancer agentincorporated polymer micelles (Matsumura and Kataoka, 2009). The cutting edge research
that is focusing on improving the current cancer treatments has utilized a new cancer treating
agent: Vaxol. This new drug is a combination of Paclitaxel and VACNO (Vascular Albumin
with Caged Nitric Oxide, Polynitroxyl Albumin). The combination of the PNA with
Paclitaxel allows for the treatment of mitotically rampant cancerous cells while also
destabilizing the condensed core of malignant tumors via the nitroxide free radicals (Desai et
al., 2006). However, the current research utilizing VACNO or PNA are all in animal models
and future research is aiming to replicate those results in human studies.
Although Paclitaxel has shown much promise in its ability to improve cancer
treatment, it still poses some difficulties to researchers attempting to use it for pharmaceutical
purposes. Paclitaxel, as previously mentioned, is unstable in the blood stream and in fact, in
most aqueous solutions, as was demonstrated in a study conducted by Amini-Fazl et al. using
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multiple aqueous solvents (Amini-Fazl et al., 2013). Therefore, it is commonly dissolved in
ethanol, a solvent which is dangerous to inject intravenously in high concentrations. How
then does one resolve the issue of conjugating Paclitaxel with a protein found commonly
throughout the blood stream? The answer lies within a High Pressure Homogenizer.
High Pressure Homogenization (HPH) has recently become a popular method for
suspending hydrophobic and insoluble drugs in a carrier medium (Nanjwade et al., 2010).
Published studies by Shelar et al. and Jacobs et al. have demonstrated how HPH can be used
in tandem with other methods to fabricate isradipin and tarazepide nanosuspensions, both
hydrophobic drugs, respectively (Shelar et al., 2013; Jacobs et al., 2000). The former of these
studies also showed that this method allowed for more bioavailability of the synthesized
drug; which was a major reason in choosing this method as the fabrication method for the
drug-protein complex for this study.
Aims of Study
The primary goal of this study was to modify nitroxyl-decorated human serum
albumin to stabilize Paclitaxel in order to synthesize a spin-albumin-stabilized Paclitaxel
Nanoparticle that will act as a cancer carrying protein with improved targeting of hypoxic
tumor cores for cancer drug delivery. The goal is to also have the nanoparticles add
additional therapeutic properties to the drug complex: namely acting as an antioxidant and
vasodilator. It is hypothesized that the synthetic complex will form as a tetramer comprised
of four identical spin-labeled albumin monomers. In order to test if the synthesis was
successful, numerous biochemical and physical analytical methods will be employed to
quantify the carrier protein’s size, structure, and properties. If the synthesis is a success, the
next step would be to test the synthesized carrier protein in preliminary pharmaceuticals to be
4

used on animals in order to test for effectiveness in the reduction of malignant tumors and
cancerous cells. The latter of the two goals for this study is time sensitive and also relies on
the success of the first step of the project.
Materials and Methods
Chemicals
Human serum albumin and modified human serum albumin, or polynitroxylated
human serum albumin were used at the protein carriers in this experiment. Paclitaxel (Figure
1) was used as the anti-cancer agent that was to be loaded into the aforementioned protein
carriers. Chloroform and ethanol (9:1 v:v) were used as solvents for preparing Paclitaxel to
be loaded while phosphate buffer (pH 7.4) was used as the solvent for HAS and PNA.

Figure 1. The structure of Paclitaxel.
Preparation of Human Serum Albumin
Human serum albumin ( HSA), obtained from Baxter, was diluted from a 25% w/v
stock solution to 5% w/v using 0.9% w/v aqueous sodium chloride. The stock HSA had
stabilizers as well as fatty acids attached to it that were removed prior to protein
modification. The stabilizers were removed by filtration using a Millipore peristaltic pump
and a 30kDa cassette filter. This filtration technique separated the solution based on the
differences in the molecular sizes of the protein versus the stabilizer allowing for the protein
5

to be isolated. Next, the HSA solution was treated with activated carbon in order to remove
the fatty acids that were conjugated with the protein. The method used to carry out the
treatment followed the guidelines published by Raymond Chen in The Journal of Biological
Chemistry (1967). Finally, the HSA was filtered through a 0.22µm syringe filter and the
solution’s pH was adjusted to biological levels (pH=7.4). An aliquot of the purified HSA was
kept to serve as a control during the analysis of the final synthesized product.
Drug Loading
In order to load Paclitaxel into HSA and PNA respectively, a high pressure liquid
homogenizer (Nano DeBEE) was used. For each 20mL processing volume of the proteindrug solution at 10mg/ml concentration, 20mg of Paclitaxel was dissolved in 0.4mL of a 9:1
solution of chloroform and ethanol while 20mL of 1% w/v HSA or PNA was formed using a
5mM Phosphate buffer solution (PBS, pH 7.4). The two solutions were gently mixed together
and then emulsified using high pressure liquid homogenization. The samples were
homogenized for two cycle times at a pressure of 1500 psi followed by homogenization for
two cycle times at 3000 psi, and finished with 8 cycles at 30,000 psi. Following
homogenization, the final dispersion underwent rotary evaporation under reduced pressure
(40°C, 15 min) in order to remove chloroform from the solution. Next, the nanoparticles
were removed by centrifugation at 6000 rpm; however, it should be noted that lower
rotational speeds may be needed depending on the state of the final dispersion in order to
preserve the composition of the nanoparticles. Finally, the supernatants for each sample
obtained by centrifugation were lyophilized and stored at -20°C until analysis.
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Analysis of Synthesized Product
After the protein carrier complex is loaded with the cancer treatment drug and spinlabeled with nitroxides, numerous analytical techniques were used to verify the structure of
the modified Taxol. The results of the analytical tests were used to quantify the level to
which the synthesized product matched the hypothesized complex that was expected to form.
The first analytical method that was employed was testing for electron spin resonance. This
method used an induced magnetic field to identify the presence of any unpaired electrons in
the complex by measuring the change in energy between the electrons with spins parallel to
the magnetic field lines and those that are flipped anti-parallel when in resonance with
microwave radiation. This analysis was only performed on modified albumin and modified
albumin- paclitaxel since they are decorated with nitroxide groups which have unpaired
electrons between nitrogen and oxygen atoms, whereas HSA does not have any free electrons
and appears as EPR inactive. The concentration of free radicals was determined in the drug
loaded sample and compared to the control sample (modified albumin) to ensure that the
addition of Paclitaxel did not alter the free radical density of the initial PNA molecule.
Next, the lyophilized samples were reconstructed in distilled water and centrifuged to
half volume through a 3kDa microfilter and the filtrate was collected in order to determine
the concentration of unbound paclitaxel. To determine amount of bound and unbound
paclitaxel, the retentate was then titrated with EtOH in order to precipitate any free proteins
and then centrifuged once more (10 min, 13.4 krpm) in order to isolate the Paclitaxel-loaded
proteins in the supernatant. Both the filtrates and supernatants had absorbance data collected
and from them and a loading factor for the synthesized drug carrier was calculated by
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observing the difference in absorption at 227nm, which is the absorption peak for Paclitaxel.
(Zhao et al., 2010).
Results
High Pressure Homogenization (HPH)
As previously mentioned, High Pressure Homogenization (HPH) is one of the few
methods that can combat the issues that arise when attempting to form drugs with molecules
that are unstable or immiscible in aqueous and organic media. Since Paclitaxel falls into this
category of immiscible drugs, HPH was used to load the drug into both HSA and PNA. The
average sizes of these proteins before undergoing HPH and drug loading are listed in Table
1; these values were used as standards in order to determine if nanoparticles were
successfully formed. The average molecular diameters of the control proteins as well as the
drug loaded proteins after undergoing HPH are listed in Table 2. When compared to the preHPH sizes, it was confirmed that this method produced nanoparticles for both control
proteins as well as both drug-loaded samples.

Table 1. Comprehensive physical data summary of control protein sizes, HSA and PNA, before
undergoing high pressure liquid homogenization.
Sample Name
Z-Ave
PdI
Pk 1
Pk 2
Pk 3
Pk 1
Pk 2
Peak 3
Mean Int Mean Int Mean Int Area
Area
Area
Int
Int
Intensit
y
d.nm
d.nm
d.nm
d.nm
%
%
%
PNA Original
11.26 0.224
12.57
2.623
0
94.5
5.5
0
HSA Original
30.24 0.651
100.2
8.495
0
73
27
0

8

Table 2. Comprehensive data summary of control protein sizes, HSA and PNA, along with
experimental drug loaded protein sizes, HSA-PTX and PNA-PTX, after undergoing high pressure liquid
homogenization.
Sample
Z-Ave PdI
Pk 1 Mean Pk 2 Mean
Pk 3
Pk 1 Area
Pk 2
Peak 3
Name
Int
Int
Mean Int
Int
Area
Area
Int
Intensity
d.nm
d.nm
d.nm
d.nm
%
%
%
Free
149.5 0.226
187.2
0
0
100
0
0
albumin
PNA
133.7 0.437
188.7
10.09
0
92.8
7.2
0
HSA-PTX
1765
1
69.46
0
0
100
0
0
PNA-PTX 375.9 0.388
204.1
0
0
100
0
0

Figure 2 shows the size distribution peaks versus peak intensity for the two drug
loaded samples, HSA-PTX and PNA-PTX, respectively. However, these figures only show
intensity data in the domain for nanoparticles and it should be noted that there were large
absorption peaks outside of this range that were centrifuged out after the average diameters
were measured, therefore the average molecular sizes in the table are skewed from the
purified samples that were collected following the measurements.
(a)
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(b)

Figure 2. Size distribution by intensity of (a) drug-loaded HSA and (b) drug-loaded PNA
synthesized via high pressure liquid homogenization before lyophilization.
In order to preserve the nanoparticles after homogenization the samples were freeze
dried via lyophilization. Following lyophilization the average molecular sizes of the
nanoparticles were measure once again (Table 3).
Table 3. Comprehensive data summary of control protein sizes, HSA and PNA, along with
experimental drug loaded protein sizes, HSA-PTX and PNA-PTX, after undergoing lyophilization.
Sample
Name

Free HSA 1
HSA-PTX 1
Free PNA 1
PNA-PTX 1

Z-Ave

d.nm
124.4
804.2
180.9
719.5

PdI

0.328
0.716
0.284
0.787

Pk 1
Mean
Int

Pk 2
Mean Int

Pk 3
Mean Int

Pk 1
Area
Int

Pk 2
Area
Int

d.nm
175.9
86.81
10.1
59.63

d.nm
0
9.169
82.77
7.34

d.nm
0
0
0
0

%
100
89.1
55.1
82

%
0
10.9
44.9
18

Peak 3
Area
Intensit
y
%
0
0
0
0

Additionally, the two drug-loaded samples had their molecular diameters measured
against their peak intensities after being lyophilized. It was observed that the freeze drying
process resulted in the reduction of the average nanoparticle size in both drug-loaded samples
(Figure 3). Similar to the skewing that occurred with the average molecule sizes before
lyophilization, the same patterns in the data was observed in Table 3 when compared to the
nanoparticle signals recorded for the drug loaded samples. Once again, this was due to the
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size distribution by intensity only recording data over a set range whereas the comprehensive
data in Table 3 averaged all molecule sizes present in the sample.
(a)

(b)

Figure 3. Size distribution by intensity of (a) drug-loaded HSA and (b) drug-loaded PNA
synthesized via high pressure liquid homogenization after lyophilization.
Electron Spin Resonance (ESR)
The nitroxide density on the synthesized drug carrier was determined using Electron
Spin Resonance (ESR). After a series dilution was performed in order to create a standard
curve of concentration versus second integration values for stock PNA (100mg/mL), the
second integration values for the reconstructed PNA and PNA-PTX nanoparticles were
measured and converted to concentrations, as shown in Figure 4.
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ESR Second Integration

3000
2500

y = 35.109x - 32.757

2000
1500

Standard Curve

1000

PNA

500

PNA-PTX

0
0

20

40

60

80

100

Concentration (μM)

Figure 4. Standard curve produced by a series dilution of stock modified albumin of electron
spin resonance second integration values versus concentration of modified albumin. The
concentrations of reconstructed PNA and PNA-PTX are shown as intersections of their
second integration values with the standard curve.
These values were then used along with dilution factors and absorbance values at
280nm in order to calculate the ratio of nitroxide free radicals on the surface of PNA and
PNA-PTX. These ratios were then compared to the ratio present in the stock solution of

Absorption (280nm)

modified albumin (Figure 5).
1
y = 95.185x - 0.0502
PNA-PTX

0.8
0.6
0.4

PNA

0.2
0
0

0.005

0.01

0.015

Linear (Standard
Curve)

Concentration (1/Dilution Factor)

Figure 5. Standard curve produced by a series dilution of stock modified albumin of
absorption values at 280nm versus concentration. The concentrations of reconstructed PNA
and PNA-PTX are shown as intersections of their absorption values with the standard curve.
Absorbance Spectra
Once it was determined that the addition of Paclitaxel only slightly altered the surface
composition of the free radicals, the number of loaded drug molecules were calculated as a
ratio of milligrams of Paclitaxel to milligrams of PNA. This ratio was determined by
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examining normalized absorption spectra for the drug-loaded samples and comparing them to
the unloaded samples. The filtrates and supernatants from both controls and experimental
proteins were analyzed via spectroscopy (Figures 6 and 7). Specifically, the difference in
absorption peaks at 227nm was quantified, as this is the absorption wavelength for Paclitaxel,
and used in conjugation with a standard curves for PNA absorbance at 280nm and Paclitaxel
absorbance at 227nm (Table 4, Figure 5, and Figure 8).
(a)

(b)
2

1

1.5

0.8

1

HSA
HSA-PTX

0.5

0.6

HSA

0.4

HSA-PTX

0.2
0
190

240

0

290

195

-0.5

245

295

Figure 6. (a) Normalized absorption spectrums for HSA (4x dilution) and HSA-PTX (4x
dilution) filtrates. (b) Normalized absorption spectrums for HSA (1H2O:7EtOH and 4x
dilution) and HSA-PTX (1H2O:7EtOH and 4x dilution) supernatants.
(a)

(b)
2

2.5

1.5

2

1

PNA

1.5

PNA-PTX

0.5

PNA

1

PNA-PTX

0.5
0
190

240

0

290

195

-0.5

245

295

Figure 7. (a) Normalized absorption spectrums for PNA (4x dilution) and PNA-PTX (4x
dilution) filtrates. (b) Normalized absorption spectrums for PNA (1H2O:7EtOH and 5x
dilution) and PNA-PTX (1H2O:7EtOH and 4x dilution) supernatants.
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Table 4. Differences in absorbance at 227nm for the filtrates and supernatants of the drugloaded samples compared to their respective controls.
HSA/HSA-PTX
Filtrate

HSA/HSA-PTX
Supernatant

PNA/PNA-PTX
Filtrate

PNA/PNA-PTX
Supernatant

Absorption
Difference at
227nm

-0.056956212

0.199381791

-0.019078095

0.124223441

Absorbance (227nm)

Compound

2
1.5

y = 331.31x - 0.7606
PNA-PTX

1
0.5
0
0.002

Linear (Standard
Curve)
0.003

0.004

0.005

0.006

0.007

Concentration (1/Dilution Factor)

Figure 8. Standard curve produced by a series dilution of 9mM Paclitaxel of absorption
values at 227nm versus concentration. The concentration of reconstructed PNA-PTX is
shown as an intersection of its absorption values with the standard curve.
Discussion
Paclitaxel is an FDA approved cancer treatment that has been shown to have
beneficial consequences for impacting the size of tumors in patients with cancer. Despite its
potential benefits, Paclitaxel still had issues with respect to its ease of delivery that made
treatment with the drug especially difficult. Paclitaxel’s instability in aqueous solutions leads
to low efficiency in intravenous injections and its solubility in ethyl alcohol is incompatible
with the human bloodstream. As a result, much research has been conducted to come up with
a potential answer to these drug delivery issues: carrier proteins.
Protein conjugation has made great strides in assuaging the difficulties of effective
cancer treatment with Paclitaxel, such as increasing the stability and half-life of the drug in
human vasculature (Kratz, 2008). However, despite the success protein conjugation has had
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with making the drug more stable, it did not make the drug completely ideal. Most notable of
the remaining issues with the drug was its ability to target and penetrate tumors. In 2009
Desai and coworkers attempted further understand the drugs targeting issue by studying the
extent to which Paclitaxel conjugated albumin penetrated tumors located in the cerebral and
cervical region of patients. What they found was that patients whose tumors had higher
SPARC secretion had an increase in drug delivery efficiency. These results were concluded
to be a consequence of SPARC’s albumin-binging properties.
What then for the patients who do not have high SPARC expression to help improve
drug targeting? According to the previously mentioned 2006 study conducted by Kaul et al.,
one of most effective antioxidants used in the study for inhibiting sickle cell adhesion was
PNA. PNA was shown to result in no post-capillary blockage by adhered sickle cells as well
as almost complete inhibition of said adhesion by PNA. Therefore it was hypothesized for
this study that if Paclitaxel was loaded onto PNA instead of HSA, then the antioxidant nature
of the protein carrier would target the hypoxic core of metastasized tumors, thus improving
drug delivery efficiency for SPARC positive and SPARC negative patients alike.
In order to synthesize this new modified albumin drug carrier protein HPH was used
so as to preserve the chemical structure of Paclitaxel in an otherwise unstable solvent. The
size data obtained from the high pressure homogenizer before lyophilization indicated that
the synthesized nanoparticles were of the correct size range (100-200nm) to be effective in
medicinal use for both HSA and PNA. However, after lyophilization there was a noted
decrease in the nanoparticle sizes for PNA. After preserving the samples by rapid freeze
drying, the analytical steps of the project were then carried out.
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One of the main draws of using PNA as a drug carrier versus HSA is that the free
radical groups allow the protein to target and penetrate the hypoxic core of tumors.
Therefore, it was important to verify that conjugating Paclitaxel with PNA did not interfere
with the nitroxide groups on the protein’s surface that provide the previously mentioned antitumor benefit. In order to determine if the drug loaded had any effect on the PNA’s free
radical surface density Electron Spin Resonance was used as the first analytical technique for
determining the physical characteristics of the newly synthesized drug carrier protein
complex. The samples of PNA-PTX and PNA had concentrations similar to samples
produced for the standard curve based on their second integration values, therefore the
sample’s intensity peaks and absorption values at 280nm were used to calculate a ratio of
nitroxides on the samples which were then compared to the known nitroxide density on the
stock PNA from which the samples were made.
𝐹𝑟𝑒𝑒 𝑅𝑎𝑑𝑖𝑐𝑎𝑙 𝑅𝑎𝑡𝑖𝑜(𝐹𝑅𝑅) =
PNA: 𝐹𝑅𝑅 =
PNA-PTX: 𝐹𝑅𝑅 =

(𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 𝑓𝑜𝑟 𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛)(𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 𝑎𝑡 280𝑛𝑚)

(160)(317.7001)
(.084455)(10)

= 60,188.28489

(133.5406277)(387.89486)

𝑃𝑁𝐴−𝑃𝑇𝑋 𝐹𝑅𝑅
𝑃𝑁𝐴 𝐹𝑅𝑅

(𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 𝑓𝑜𝑟 𝐸𝑆𝑅)(𝐸𝑆𝑅 𝑆𝑒𝑐𝑛𝑜𝑑 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑉𝑎𝑙𝑢𝑒)

(.10634)(10)

= 48,711.41911

48,711.41911

= 60,188.28489 = 0.809

(1)
(2)
(3)
(4)

Based on the data and above calculations (Equation 1-4), there was a 4:5 ratio of nitroxides
on the reconstructed PNA versus the reconstructed PNA-PTX. These values suggest that the
addition of Paclitaxel to the proteins slightly altered the number of free radicals that were
originally present in each molecule by a 20% reduction. However, since the drug loaded
protein and original sample are still comparable in free radical density, the vasodilation
effects may still be present in both; however further research would be needed in order to
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conclude this hypothesis. Also, it is not clear the mechanism of the reduction during the
formation of nanoparticles.
Following EPR, the samples were centrifuged and filtered according to the methods
listed above in order to isolate the bound Paclitaxel-protein complexes. Absorption spectra
were then obtained for the filtrates and supernatants of all samples to be used in calculating
the number of loaded drug molecules on each protein. The calculations in equations 5-9 were
performed using multiple standard curves (Figures 5 and 8) as well as of the absorption
difference at the wavelength 227nm, the absorbance peak for Paclitaxel.
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓
1
207.548

4𝑚𝑔 𝑃𝑁𝐴−𝑃𝑇𝑋
10𝑚𝐿 𝐻2 𝑂

(9 ∙ 10−3

𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓

𝑚𝑜𝑙
𝐿

853.906𝑔

)(

4𝑚𝑔 𝑃𝑁𝐴−𝑃𝑇𝑋
10𝑚𝐿 𝐻2 𝑂
1

335.847

(100

𝑎𝑡 227𝑛𝑚: 0.83573 → 207.548𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (5)

1𝑚𝑜𝑙

1𝐿

1000𝑚𝑔

) (1000𝑚𝐿) (

1𝑔

𝑚𝑔 𝑃𝑇𝑋

) = 0.0362 𝑚𝐿 𝐻

2𝑂

(6)

𝑎𝑡 280𝑛𝑚: 0.23319 → 335.847𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (7)

𝑚𝑔 𝑃𝑁𝐴
𝑚𝐿 𝐻2 𝑂

) = 0.29775

𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝐶𝑜𝑛𝑣𝑒𝑟𝑡𝑒𝑑 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑠 =

𝑚𝑔 𝑃𝑁𝐴

𝑚𝑔 𝑃𝑇𝑋
)
𝑚𝐿 𝐻2 𝑂
𝑚𝑔 𝑃𝑁𝐴
(0.29775
)
𝑚𝐿 𝐻2 𝑂

(0.0362

(8)

𝑚𝐿 𝐻2 𝑂
𝑚𝑔 𝑃𝑇𝑋

= 0.122 𝑚𝑔 𝑃𝑁𝐴

(9)

It was determined that the modified HSA molecules had an average of 0.122mg of Paclitaxel
per 1mg of PNA. The amount of loaded Paclitaxel molecules on PNA was comparable to the
amount loaded to unmodified HSA in commercially available Paclitaxel (11.1%).
Overall Implications of Research
As previously mentioned, cancer has become a very “hot-button” issue with the
public and thus has been the focus of many recent scientific research projects. This field of
study is of particular interest because of new methods of drug delivery that offer promising
results with respect to treating cancer patients. For example, it has recently been shown that
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spin labeled albumin can increase blood flow while also increasing the permeability of the
drug into tumors in mice (Sugawara et al, 2001). Therefore it was this project’s goal to
combine the tumor specific benefits of nitroxides with the protein carrier benefits of
Paclitaxel loaded PNA to increase the efficiency of drug delivery to tumors in cancerous
patients. If this project is a success, then the result would be an increased effectiveness in
cancer treatment by incorporating the ability to break up the tightly packed core of tumors to
an FDA approved cancer treatment drug. This added benefit, which stems from the
nanoparticles being in a complex with Paclitaxel, ultimately would allow for the cancer
treatment to be more effective in that it could deliver the drug into the core of the cancerous
cell cluster instead of just to the surface. Also, the antioxidants would have the added benefit
of intercepting harmful radicals in the body as well as alleviating hypertension and vascular
blockage; however, more research would be needed to validate these side effects.
Conclusion
This study aimed to synthesize Paclitaxel conjugated polynitroxylated albumin
nanoparticles to be used as a means of increasing the effectiveness of cancer treatment by
specifically enhancing the specificity of the drug-carrier for hypoxic tumor cores via
nitroxide free radicals. Results showed that the anti-cancer drug was successfully conjugated
with modified albumin by means of high pressure homogenization and that nanoparticles of
the associated molecules were able to be isolated by centrifugation. Data from the high
pressure homogenizer showed that the isolated nanoparticles were of the correct size, 100200nm, to be used medicinally. Analysis of the electron spin resonance data showed that
loading Paclitaxel only slightly altered the nitroxide density initially present in the stock
solution of modified albumin used in the experiment. This suggests that the vasodilation and
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tumor targeting benefits of the free radicals would most likely be present upon application of
the synthesized molecules intravenously; once again, further study would be needed in order
to test this. Finally, the absorption data obtained from this study allowed for the
quantification of the number of Paclitaxel molecules that were loaded to each modified
albumin proteins. When compared to the number of loaded Paclitaxel molecules loaded to
unmodified human serum albumin observed in other studies, as well as the Paclitaxel to HSA
ratio found in commercially available Paclitaxel, this method allowed for an equal number of
Paclitaxel molecules to be loaded to modified PNA. (Paál et al.).
In order to fully quantify the physical characteristics of the synthesized protein
complex, more analytical processes will be conducted in the future. One such method will be
High Performance Liquid Chromatography (HPLC). The data obtained from running an
HPLC analysis will determine the different forms of Paclitaxel that are bound to the modified
albumin and the extent to which the cancer drug degraded during preparation. Pending the
results of the HPLC analysis, the next step in determining the effectiveness of the
synthesized drug carrier protein would be in vitro testing with cancerous cells.
When comparing the absorption peaks in figures 2 and 3 it was observed that there
was a decrease in nanoparticle size upon lyophilization. This decrease in size was not
expected and further study would be needed in order to determine, and fix, the cause for the
change in nanoparticle size. Despite this issue, this study was successful in producing
Paclitaxel conjugated polynitroxylated albumin nanoparticles that could prove useful in more
effective cancer treatment.
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